Gracell Biotechnologies Inc.
https://www.gracellbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gracell Biotechnologies Inc.
The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?
Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.
CGT Landscape: Recent Approvals, Deals And 2024 Catalysts
The last quarter of 2023 was an exciting one for the cell and gene therapy sector – with the first-ever approval for a CRISPR-based therapeutic in the US and an increase in Phase III trials in the overall CGT pipeline.
J&J/Legend Tout Carvykti In Earlier Lines As Competitors Move In
They have new data for the CAR-T after one to three lines of multiple myeloma treatment and Phase III patient-reported outcomes data, but Gilead and Gracell are nipping at the companies’ and BMS’s heels.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Gracell Biotechnologies Co., Ltd.
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Gracell Biotechnology Ltd.
- Shanghai Gracell Biotech
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice